Xvivo Perfusion AB (publ) (LON:0RKL)
London · Delayed Price · Currency is GBP · Price in SEK | Market Cap | 637.07M +50.9% |
| Revenue (ttm) | 69.62M +8.8% |
| Net Income | 6.89M -20.5% |
| EPS | 0.22 -20.0% |
| Shares Out | n/a |
| PE Ratio | 92.49 |
| Forward PE | 58.56 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,334 |
| Open | 269.80 |
| Previous Close | 262.20 |
| Day's Range | 264.20 - 271.60 |
| 52-Week Range | 160.80 - 314.00 |
| Beta | 1.46 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 22, 2026 |
About Xvivo Perfusion AB
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermi... [Read more]
Financial Performance
In 2025, Xvivo Perfusion AB's revenue was 812.17 million, a decrease of -1.25% compared to the previous year's 822.42 million. Earnings were 25.16 million, a decrease of -85.39%.
Financial numbers in SEK Financial StatementsNews
Xvivo Perfusion AB Earnings Call Transcript: Q2 2026
Q2 delivered 36% organic sales growth year-over-year, with strong momentum in thoracic and abdominal segments and robust EBITDA and cash flow. Regulatory progress continues for heart and liver products, while investments focus on commercial expansion and production scale-up.
Xvivo Perfusion AB Quarterly report: Q2 2026
Xvivo Perfusion AB has published its Q2 2026 quarterly earnings report on July 14, 2026.
Xvivo Perfusion AB Slides: Q2 2026
Xvivo Perfusion AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 14, 2026.
Interim Report January - June 2026
GOTHENBURG, SE / ACCESS Newswire / July 14, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Second quarter 2026 (Apr-Jun) Net sales amounted to SEK 239.0 million (178.3), corresponding to a g...
Bulletin from Annual General Meeting in XVIVO Perfusion AB (publ)
GOTHENBURG, SE / ACCESS Newswire / April 27, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV): The following resolutions were passed at the Annual General Meeting (the "AGM") of XVIVO Perfusio...
Xvivo Perfusion AB Earnings Call Transcript: Q1 2026
Record Q1 sales with 23% organic growth and strong cash flow, driven by robust thoracic and abdominal segment performance. Regulatory milestones for Heart Assist and Liver Assist are progressing, with significant clinical trial successes and expanding adoption in key markets.
Xvivo Perfusion AB Quarterly report: Q1 2026
Xvivo Perfusion AB has published its Q1 2026 quarterly earnings report on April 24, 2026.
Xvivo Perfusion AB Slides: Q1 2026
Xvivo Perfusion AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 24, 2026.
Notice To Attend the Annual General Meeting in XVIVO Perfusion Ab (Publ)
GOTHENBURG, SE / ACCESS Newswire / March 19, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - (the "Company"), reg. no. 556561-0424, with its registered office in Mölndal, gives notice of th...
The Nomination Committee of XVIVO Perfusion AB (publ) Proposes Emil Billbäck and Anne-Karen Hunt as New Members of the Board of Directors
GOTHENBURG, SWEDEN / ACCESS Newswire / February 20, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Ahead of the Annual General Meeting to be held on 27 April 2026, the Nomination Committee p...
Xvivo Perfusion AB Earnings Call Transcript: Q4 2025
Q4 2025 saw 10% organic growth and record EBITDA margin, with strong performance in thoracic and abdominal segments. Strategic investments and restructuring are set to drive growth in 2026, though profitability will be moderated by expansion efforts. Regulatory milestones for heart and liver products remain key.
Xvivo Perfusion AB Annual report: Q4 2025
Xvivo Perfusion AB has published its Q4 2025 annual report on January 27, 2026.
Xvivo Perfusion AB Quarterly report: Q4 2025
Xvivo Perfusion AB has published its Q4 2025 quarterly earnings report on January 27, 2026.
Xvivo Perfusion AB Slides: Q4 2025
Xvivo Perfusion AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on January 27, 2026.
Xvivo Perfusion AB Transcript: 44th Annual J.P. Morgan Healthcare Conference
Aims to revolutionize organ transplantation by increasing organ availability and improving outcomes through advanced perfusion technologies. Heart product launch and regulatory milestones are key upcoming drivers, with a strong focus on expanding market reach and service offerings.
Xvivo Perfusion AB Slides: 44th Annual J.P. Morgan Healthcare Conference
Xvivo Perfusion AB has posted slides in relation to its latest quarterly earnings report, which was published on January 14, 2026.
Xvivo Perfusion AB Earnings Call Transcript: Q3 2025
Q3 2025 saw 6% organic growth (excluding Heart trial revenue), strong abdominal segment performance, and EBITDA recovery. Strategic investments in U.S. services and partnerships aim to drive future growth, while regulatory timelines for Heart and Liver remain key uncertainties.
Xvivo Perfusion AB Quarterly report: Q3 2025
Xvivo Perfusion AB has published its Q3 2025 quarterly earnings report on October 23, 2025.
Xvivo Perfusion AB Slides: Q3 2025
Xvivo Perfusion AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 23, 2025.